159 related articles for article (PubMed ID: 21813738)
1. Metallofullerene-based nanoplatform for brain tumor brachytherapy and longitudinal imaging in a murine orthotopic xenograft model.
Shultz MD; Wilson JD; Fuller CE; Zhang J; Dorn HC; Fatouros PP
Radiology; 2011 Oct; 261(1):136-43. PubMed ID: 21813738
[TBL] [Abstract][Full Text] [Related]
2. Science to practice: can theranostic fullerenes be used to treat brain tumors?
Bulte JW
Radiology; 2011 Oct; 261(1):1-2. PubMed ID: 21931135
[TBL] [Abstract][Full Text] [Related]
3. Metallofullerene-nanoplatform-delivered interstitial brachytherapy improved survival in a murine model of glioblastoma multiforme.
Wilson JD; Broaddus WC; Dorn HC; Fatouros PP; Chalfant CE; Shultz MD
Bioconjug Chem; 2012 Sep; 23(9):1873-80. PubMed ID: 22881865
[TBL] [Abstract][Full Text] [Related]
4. Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of (177)Lu and comparison of its efficacy with that of (90)Y and residualizing (131)I.
Stein R; Govindan SV; Chen S; Reed L; Richel H; Griffiths GL; Hansen HJ; Goldenberg DM
J Nucl Med; 2001 Jun; 42(6):967-74. PubMed ID: 11390564
[TBL] [Abstract][Full Text] [Related]
5. Preliminary evaluation of (177)Lu-labeled knottin peptides for integrin receptor-targeted radionuclide therapy.
Jiang L; Miao Z; Kimura RH; Liu H; Cochran JR; Culter CS; Bao A; Li P; Cheng Z
Eur J Nucl Med Mol Imaging; 2011 Apr; 38(4):613-22. PubMed ID: 21153409
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Orthotopic U251 Human Glioblastoma Multiforme Tumors in NRG Mice by Convection-Enhanced Delivery of Gold Nanoparticles Labeled with the β-Particle-Emitting Radionuclide,
Georgiou CJ; Cai Z; Alsaden N; Cho H; Behboudi M; Winnik MA; Rutka JT; Reilly RM
Mol Pharm; 2023 Jan; 20(1):582-592. PubMed ID: 36516432
[TBL] [Abstract][Full Text] [Related]
7. New peptide receptor radionuclide therapy of invasive cancer cells: in vivo studies using 177Lu-DOTA-AE105 targeting uPAR in human colorectal cancer xenografts.
Persson M; Rasmussen P; Madsen J; Ploug M; Kjaer A
Nucl Med Biol; 2012 Oct; 39(7):962-9. PubMed ID: 22739362
[TBL] [Abstract][Full Text] [Related]
8. In vivo and in vitro evaluation of
Zhang J; Wang Z; Liu H; Cai L; Feng Y; Zhou L; Wei H; Xie Y; Chen Y
Hell J Nucl Med; 2019; 22(2):103-110. PubMed ID: 31273351
[TBL] [Abstract][Full Text] [Related]
9. Anti-EGFRvIII monoclonal antibody armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands.
Hens M; Vaidyanathan G; Zhao XG; Bigner DD; Zalutsky MR
Nucl Med Biol; 2010 Oct; 37(7):741-50. PubMed ID: 20870149
[TBL] [Abstract][Full Text] [Related]
10. Optimizing lutetium 177-anti-carbonic anhydrase IX radioimmunotherapy in an intraperitoneal clear cell renal cell carcinoma xenograft model.
Muselaers CH; Oosterwijk E; Bos DL; Oyen WJ; Mulders PF; Boerman OC
Mol Imaging; 2014; 13():1-7. PubMed ID: 24824962
[TBL] [Abstract][Full Text] [Related]
11. Experimental iodine-125 seed irradiation of intracerebral brain tumors in nude mice.
Verhoeff JJ; Stalpers LJ; Coumou AW; Koedooder K; Lavini C; Van Noorden CJ; Haveman J; Vandertop WP; van Furth WR
Radiat Oncol; 2007 Sep; 2():38. PubMed ID: 17897452
[TBL] [Abstract][Full Text] [Related]
12. Rhenium-186 liposomes as convection-enhanced nanoparticle brachytherapy for treatment of glioblastoma.
Phillips WT; Goins B; Bao A; Vargas D; Guttierez JE; Trevino A; Miller JR; Henry J; Zuniga R; Vecil G; Brenner AJ
Neuro Oncol; 2012 Apr; 14(4):416-25. PubMed ID: 22427110
[TBL] [Abstract][Full Text] [Related]
13. Intratumorally Injected 177Lu-Labeled Gold Nanoparticles: Gold Nanoseed Brachytherapy with Application for Neoadjuvant Treatment of Locally Advanced Breast Cancer.
Yook S; Cai Z; Lu Y; Winnik MA; Pignol JP; Reilly RM
J Nucl Med; 2016 Jun; 57(6):936-42. PubMed ID: 26848176
[TBL] [Abstract][Full Text] [Related]
14. DOTA conjugate with an albumin-binding entity enables the first folic acid-targeted 177Lu-radionuclide tumor therapy in mice.
Müller C; Struthers H; Winiger C; Zhernosekov K; Schibli R
J Nucl Med; 2013 Jan; 54(1):124-31. PubMed ID: 23236020
[TBL] [Abstract][Full Text] [Related]
15. DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours.
Zhang H; Schuhmacher J; Waser B; Wild D; Eisenhut M; Reubi JC; Maecke HR
Eur J Nucl Med Mol Imaging; 2007 Aug; 34(8):1198-208. PubMed ID: 17262215
[TBL] [Abstract][Full Text] [Related]
16. Targeted antisense radiotherapy and dose fractionation using a (177)Lu-labeled anti-bcl-2 peptide nucleic acid-peptide conjugate.
Liu D; Balkin ER; Jia F; Ruthengael VC; Smith CJ; Lewis MR
Nucl Med Biol; 2015 Sep; 42(9):704-10. PubMed ID: 26081917
[TBL] [Abstract][Full Text] [Related]
17. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
[TBL] [Abstract][Full Text] [Related]
18. Multimodal Imaging of 2-Cycle PRRT with
Albrecht J; Exner S; Grötzinger C; Prasad S; Konietschke F; Beindorff N; Kühl AA; Prasad V; Brenner W; Koziolek EJ
J Nucl Med; 2021 Mar; 62(3):393-398. PubMed ID: 32859703
[TBL] [Abstract][Full Text] [Related]
19. Are gadolinium contrast agents suitable for gadolinium neutron capture therapy?
De Stasio G; Rajesh D; Casalbore P; Daniels MJ; Erhardt RJ; Frazer BH; Wiese LM; Richter KL; Sonderegger BR; Gilbert B; Schaub S; Cannara RJ; Crawford JF; Gilles MK; Tyliszczak T; Fowler JF; Larocca LM; Howard SP; Mercanti D; Mehta MP; Pallini R
Neurol Res; 2005 Jun; 27(4):387-98. PubMed ID: 15949236
[TBL] [Abstract][Full Text] [Related]
20. Targeted systemic radiotherapy with scVEGF/177Lu leads to sustained disruption of the tumor vasculature and intratumoral apoptosis.
Blankenberg FG; Levashova Z; Goris MG; Hamby CV; Backer MV; Backer JM
J Nucl Med; 2011 Oct; 52(10):1630-7. PubMed ID: 21890879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
